STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2014 by analyst upside · 2026-08-13
MRVI
Maravai LifeSciences Holdings, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+26.3%
implied upside to consensus target
Current Price $5.78
Consensus Target $7.3
Bull Target $8.0
Bear Target $6.5
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
2
Sell
0
52-Week Low $2.28
52-Week High $7.44
YTD Return +70.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.53
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $209M
Profit Margin -37.1%
52-WEEK RANGE
52-Week Low $2.28
52-Week High $7.44
Current Price $5.78
Bear Target $6.5
Bull Target $8.0
● Now $5.78 ● Target $7.3
TRADING DATA
Avg Volume 2.8M
YTD Return +70.0%
Analyst Count 5
Consensus Buy
Upside to Target +26.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Maravai LifeSciences Holdings, Inc. (MRVI) is currently trading at $5.78 with a Wall Street consensus price target of $7.3, implying potential upside of 26.3% over the next 12 months. 5 analysts currently cover MRVI, with a consensus rating of Buy - 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $6.5.

MRVI operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 70.0% year-to-date and is currently trading near the upper end of its 52-week range of $2.28 – $7.44.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MRVI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2025-12-15 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2025-08-12 Building track record
Craig-Hallum - Reiterated
Buy → Buy 2025-08-12 Building track record
Craig-Hallum - Reiterated
Buy → Buy 2025-05-13 Building track record
Baird - Reiterated
Neutral → Neutral 2025-05-13 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2025-03-25 Building track record
UBS - Reiterated
Neutral → Neutral 2025-03-21 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
14/30
Consensus clarity
25/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →